US FDA's Generics Program Reaches 'Steady State' Milestone
Executive Summary
OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.
You may also be interested in...
Generics Review Data From US FDA Reveals Positives, Negatives For Industry
While a decline in complete response letters in FY 2023 is good, the continued drop in ANDA submissions could be a bad sign for the industry’s long-term health, a former FDA official worries.
Generics Review Data From US FDA Reveals Positives, Negatives For Industry
While a decline in complete response letters in FY 2023 is good, the continued drop in ANDA submissions could be a bad sign for the industry’s long-term health, a former FDA official worries.
Next US FDA Generics Leader Must Have ‘Frank Conversations’ With Colleagues, Industry, Former OGD Director Says
Susan Rosencrance, who helped negotiate GDUFA III, will take over as acting director of the Office of Generic Drugs following Sally Choe’s departure on 8 October. Former OGD head Uhl says the director needs to be the ‘number one advocate for the generic drug program inside the agency.’